Dr. Robert Coleman (onclive)
Aug 26, 2016
Robert Coleman, MD, professor in
the department of Gynecologic Oncology and Reproductive Medicine,
University of Texas MD Anderson Cancer Center, discusses BRCA testing
for ovarian cancer.
The current recommendations for BRCA testing say that high-grade serous
patients should get it at the diagnosis. However, recent data has shown
that other histology types have enough of a frequency that it's worth
testing there as well, says Coleman. Outside mucinous tumors, germline
testing has been done across the board, says Coleman.
Germline and somatic BRCA alterations look similar, says Coleman. There
isn’t much data on other non-BRCA germline mutations that might be
associated with familial or genetic risk, and what their likelihood is,
but that field is expanding, says Coleman.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.